Ameritas Investment Partners’s Galectin Therapeutics GALT Stock Holding History

Ameritas Investment Partners’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,995	Closed	-$2.43K	–	3249
2025 Q1	$2.43K	Hold	1,995	–	–	﹤0.01%	3064
2024 Q4	$2.57K	Hold	1,995	–	–	﹤0.01%	3092
2024 Q3	$5.49K	Hold	1,995	–	–	﹤0.01%	3027
2024 Q2	$4.51K	Buy	+1,995	New	+$6.06K	﹤0.01%	3041
2021 Q2	–	Sell	-2,845	Closed	-$6K	–	3127
2021 Q1	$6K	Hold	2,845	–	–	﹤0.01%	2977
2020 Q4	$6K	Hold	2,845	–	–	﹤0.01%	2937
2020 Q3	$8K	Hold	2,845	–	–	﹤0.01%	2806
2020 Q2	$9K	Hold	2,845	–	–	﹤0.01%	2770
2020 Q1	$6K	Hold	2,845	–	–	﹤0.01%	2750
2019 Q4	$8K	Hold	2,845	–	–	﹤0.01%	2803
2019 Q3	$10K	Hold	2,845	–	–	﹤0.01%	2747
2019 Q2	$12K	Buy	+2,845	New	+$12.3K	﹤0.01%	2721

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameritas Investment Partners's GALT Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Galectin Therapeutics (GALT) in Q2 2025, closing a stake of 1,995 shares — an estimated $2.43K sold.

Ameritas Investment Partners first reported a position in GALT in Q2 2019 and held it in 12 quarters. The position peaked at $12K in Q2 2019. 86 funds tracked by Wall St. Rank hold GALT as of Q2 2025.

Ameritas Investment Partners reported no remaining Galectin Therapeutics position as of Q2 2025 after selling out during the quarter.
Ameritas Investment Partners sold 1,995 Galectin Therapeutics shares in Q2 2025, an estimated $2.43K.
Ameritas Investment Partners first reported a position in Galectin Therapeutics in Q2 2019 and held it in 12 quarters.
Ameritas Investment Partners's Galectin Therapeutics position peaked at $12K in Q2 2019.
86 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.